Abstract
Multipotent mesenchymal stem (stromal) cells (MSCs) have shown promising therapeutic effects in preclinical models of both acute respiratory distress syndrome (ARDS) and sepsis. Although initial research focused on the ability of MSCs to engraft at sites of tissue injury, increasing evidence suggests that MSCs have their therapeutic effects through mechanisms unrelated to long-term incorporation into host tissue. One of the most compelling of these pathways is the ability of MSCs to interact with injured tissue through the release of soluble bioactive factors. This Review provides an overview of the general properties of MSCs, and then outlines ways in which the paracrine effects of MSCs might reduce lung injury and enhance lung repair in ARDS and sepsis. Finally, we summarise ongoing challenges in MSC research and identify areas in which the discipline might progress in the coming years.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1016-1026 |
| Number of pages | 11 |
| Journal | The Lancet Respiratory Medicine |
| Volume | 2 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 1 2014 |
Funding
MAM reports grants from the National Heart, Lung, and Blood Institute, GlaxoSmithKline, and the National Institute of Allergy and Infectious Diseases, as well as consulting work with Cerus and Roche-Genetec (Chair of Data and Safety Monitoring Board). The other authors declare no competing interests. The authors thank Diana Lim for her excellent work in preparing the figure . MAM was supported in part by NHLBI R37HL51856 and R01HL51854.
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
